Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie 
Welcome,         Profile    Billing    Logout  
 19 Diseases   1 Trial   1 Trial   3388 News 


«12...1516171819202122232425...4849»
  • ||||||||||  Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal, Combination therapy:  Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa. (Pubmed Central) -  Oct 15, 2022   
    However, susceptibility to ceftazidime was significantly improved with the addition of avibactam (p < 0.01), and the susceptibility to C/T was improved compared to piperacillin/tazobactam (p < 0.05) These data provide in vitro evidence that I-R may not be any more effective than imipenem monotherapy against MDR CFPA. The pattern of susceptibility observed for CZA and C/T in the current study was similar to data previously reported for non-CF-associated MDR P. aeruginosa.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    PK/PD data, Journal:  Population pharmacokinetic modelling for ceftazidime-avibactam renal dose adjustments in pediatric patients 3 months and older. (Pubmed Central) -  Oct 15, 2022   
    Since there were few children with renal impairment in the ceftazidime-avibactam clinical trials, selected pediatric doses were guided by extrapolation and matching of adult exposures associated with efficacy and within established safety margins. The recommended doses for pediatric patients with estimated CrCL ≤50 mL/min/1.73 m use equivalent adjustments in dose quantity and/or administration interval (versus the corresponding age group with normal renal function) as those for adults.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Review, Journal:  Antibacterial spectrum of cefiderocol. (Pubmed Central) -  Oct 11, 2022   
    Resistance mechanisms are not directly associated with porin deficiency and or efflux pumps. On the contrary, they are related with gene mutations affecting iron transporters, AmpC mutations in the omega loop and with certain beta-lactamases such us KPC-variants determining also ceftazidime-avibactam resistance, certain infrequent extended-spectrum betalactamases (PER, BEL) and metallo-beta-lactamases (certain NDM variants and SPM enzyme).
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Preclinical, Journal:  In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program. (Pubmed Central) -  Oct 9, 2022   
    On the contrary, they are related with gene mutations affecting iron transporters, AmpC mutations in the omega loop and with certain beta-lactamases such us KPC-variants determining also ceftazidime-avibactam resistance, certain infrequent extended-spectrum betalactamases (PER, BEL) and metallo-beta-lactamases (certain NDM variants and SPM enzyme). Ceftaroline showed good activity among tested antimicrobial agents against Gram-positive species, while ceftazidime-avibactam had good activity against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Morganella morganii, Serratia marcescens and Pseudomonas aeruginosa excluding carbapenem-resistant isolates.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Ceftazidime-avibactam activity against Gram-negative respiratory isolates collected between 2018 and 2019. (Pubmed Central) -  Oct 9, 2022   
    Ceftaroline showed good activity among tested antimicrobial agents against Gram-positive species, while ceftazidime-avibactam had good activity against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Morganella morganii, Serratia marcescens and Pseudomonas aeruginosa excluding carbapenem-resistant isolates. Gram-negative respiratory isolates collected in 2018-2019 showed high susceptibility to CAZ-AVI; CAZ-AVI represents a potential treatment option against infection caused by these organisms.
  • ||||||||||  imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Phenotypes, genotypes and breakpoints: an assessment of β-lactam/ β-lactamase inhibitor combinations against OXA-48. (Pubmed Central) -  Oct 5, 2022   
    Data demonstrate that current imipenem/relebactam and ceftazidime/avibactam CLSI breakpoints are appropriate. Data also suggest that higher meropenem/vaborbactam breakpoints relative to meropenem can translate to potentially poor clinical outcomes in patients infected with OXA-48-harbouring isolates.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Observational data, Retrospective data, Journal:  Antibiotic Abuse and Antimicrobial Resistance in Hospital Environment: A Retrospective Observational Comparative Study. (Pubmed Central) -  Sep 30, 2022   
    faecium (VRE) had a lower incidence in the clinical setting, with respect to E. coli and K. pneumoniae. The data obtained in this study can support clinicians towards a rational and safe use of antibiotics for treating the infections caused by these resistant strains, to enhance the overall efficacy of the current antibiotic protocols used in the main healthcare environments.
  • ||||||||||  imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Susceptibility of OXA-48-producing Enterobacterales to imipenem-relebactam, meropenem-vaborbactam and ceftazidime-avibactam. (Pubmed Central) -  Sep 29, 2022   
    Considering the favorable efficacy and outcomes of ceftazidime-avibactam, this drug should be considered for the treatment of these severe infections in patients with liver cirrhosis, though further investigation is required. This study highlighted the lack of benefit in vitro for carbapenem-inhibitor combination compared to carbapenem alone on OXA-48-producing isolates as well as the difficulties to compared molecules since carbapenem-inhibitor combinations were not developed with the same dosage of carbapenem.
  • ||||||||||  imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Review, Journal:  Current Positioning against Severe Infections Due to Klebsiella pneumoniae in Hospitalized Adults. (Pubmed Central) -  Sep 25, 2022   
    Moreover, we reviewed and updated the most important clinical entities and the new antibiotic treatments recently developed. After analysis of the priorities outlined, this group of experts established a series of recommendations and designed a management algorithm.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Review, Journal:  Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview. (Pubmed Central) -  Sep 24, 2022   
    Moreover, extension of resistance to ceftazidime-avibactam is associated with a trade-off in the resistance to other beta-lactams and a decrease in enzyme stability. Nevertheless, the high natural stability of KPC could underlay the propensity of this enzyme to acquire in vivo mutations conferring resistance to ceftazidime-avibactam (CAZavi), particularly via insertions and deletions.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Multidrug-Resistant Gram-Negative Bacteria in Burn Patients. (Pubmed Central) -  Sep 24, 2022   
    Samples from two patients grew genetically similar C. freundii isolates that were resistant to ceftazidime-avibactam...In summary, MDR GNB colonization is common in burn patients and patient-to-patient transmission of highly resistant GNB occurs. These results emphasize the ongoing need for infection prevention and antimicrobial stewardship efforts in this highly vulnerable population.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Antimicrobial Susceptibility Testing of Clinical Isolates of Gram-Negative Bacilli Collected in Morocco by the ATLAS Global Surveillance Program from 2018 to 2020. (Pubmed Central) -  Sep 14, 2022   
    This analysis shows that changing the way in which a new antimicrobial is used within a treatment strategy has the potential for additional significant clinical and economic value. Newer β-lactam/β-lactamase inhibitor combinations such as ceftazidime-avibactam warrant testing and reporting for Enterobacterales and P. aeruginosa in Morocco given the presence of significant resistance to first-line β-lactams and fluoroquinolones, pervasive ESBLs and carbapenemases, and toxicity concerns associated with some second-line agents.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    IN VITRO TO IN VIVO: COMBATING MULTIDRUG-RESISTANT ENTEROBACTERIACAE IN THE AGE OF COVID-19 (Convention Center Exhibit Hall: Rapid Area 3A) -  Sep 11, 2022 - Abstract #CHEST2022CHEST_4161;    
    Superinfections with carbapenem-resistant enterobacteria have increased in the context of the COVID-19 pandemic and are likely to become more prevalent in our hospitals. Prompt recognition and appropriate therapeutic selection are paramount for treating these highly resistant organisms.
  • ||||||||||  Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Preclinical, Journal:  In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019. (Pubmed Central) -  Sep 10, 2022   
    IMPORTANCE After testing cefiderocol against a large collection of clinical isolates of highly antimicrobial-resistant Pseudomonas aeruginosa, we report that cefiderocol is active versus 97.4% of extensively drug-resistant (XDR) and 97.9% of multidrug-resistant (MDR) (n = 771) isolates. These data show that cefiderocol may be a treatment option for infections caused by MDR and XDR P. aeruginosa.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Evolution of Habitat-Dependent Antibiotic Resistance in Pseudomonas aeruginosa. (Pubmed Central) -  Sep 10, 2022   
    We determined that P. aeruginosa genetic trajectories toward resistance to tobramycin, ceftazidime, and ceftazidime-avibactam are different when evolving in laboratory rich medium, urine, or synthetic sputum...Consequently, the selection of AR mutations that render similar phenotypes is environment dependent. The analysis of evolution patterns toward AR requires studying growth conditions mimicking those that bacteria face during in vivo evolution.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Carbapenemase-Encoding Gene Copy Number Estimator (CCNE): a Tool for Carbapenemase Gene Copy Number Estimation. (Pubmed Central) -  Sep 10, 2022   
    An association study of 357 KPC-producing K. pneumoniae isolates and their antimicrobial susceptibility identified a significant association between the estimated bla copy number and MICs of imipenem (P < 0.001) and ceftazidime-avibactam (P < 0.001)...In this study, we describe a ready-to-use tool we developed and designated the carbapenemase-encoding gene copy number estimator (CCNE) that can be used to estimate the blaCarb copy number directly from whole-genome sequencing data, and we extended the data to support the analysis of all known blaCarb genes and some other antimicrobial resistance genes. Furthermore, CCNE can be used to interrogate the correlations between genotypes and susceptibility phenotypes and to improve our understanding of antimicrobial resistance mechanisms.